Philip Morris International (PMI) reaffirmed its full‑year 2026 diluted earnings‑per‑share (EPS) forecast at the Consumer Analyst Group of New York (CAGNY) conference, setting a range of $7.87 to $8.02 per share. The guidance represents an 11.1% to 13.1% increase over the 2025 diluted EPS guidance of $7.54, underscoring management’s confidence in the company’s trajectory.
In addition to the reported EPS range, PMI disclosed an adjusted diluted EPS range of $8.38 to $8.53 when a $0.51 per‑share adjustment is excluded. This adjusted guidance reflects a 7.5% to 9.5% rise versus the 2025 adjusted EPS of $7.54, and aligns closely with analyst expectations for the year.
The guidance update is framed by a clear historical context. PMI’s reported diluted EPS was $7.26 in 2025 and $4.52 in 2024, while the adjusted diluted EPS was $7.54 in 2025 and $6.57 in 2024. The year‑over‑year jump in both reported and adjusted EPS highlights the company’s accelerating performance and the growing contribution of its smoke‑free portfolio.
The company attributes the upward revision to continued momentum in its smoke‑free product line and expansion in the U.S. market. Smoke‑free products accounted for 41.5% of PMI’s full‑year 2025 net revenues, and the firm estimates that more than 43 million adult consumers were using its smoke‑free products as of December 31, 2025. These figures illustrate the strategic shift toward higher‑margin, lower‑regulation products that PMI has pursued aggressively over the past decade.
Management emphasized the strength of the company’s execution. Group CEO Jacek Olczak noted that 2025 delivered a fifth consecutive year of volume growth, net revenues exceeding $40 billion, and “very good operating margin expansion.” He added that the company has met its three‑year compound annual growth rate targets on operating income and EPS in just two years, positioning it to outperform its 2024‑2026 growth algorithm in 2026.
Investors reacted with caution, citing competitive pressures in the nicotine‑pouch market and a slight miss on some analyst expectations for the 2026 guidance. The market’s tempered response reflects the balance between PMI’s strong growth narrative and the headwinds posed by rivals such as British American Tobacco in the U.S. and regulatory uncertainties in key markets.
The reaffirmation signals PMI’s continued confidence in its strategic pivot to smoke‑free products and its U.S. expansion. By maintaining the 2026 guidance, the company demonstrates that it expects to sustain margin expansion and revenue growth, while also managing the competitive and regulatory headwinds that accompany its transition to a lower‑risk product mix. The guidance update therefore provides a clear benchmark for future performance and reinforces PMI’s long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.